Lancet Review: mRNA Vaccines 94% Effective Against COVID-19 Death, Serious Adverse Events Remain Rare Across Billions of Doses
核心洞察
A comprehensive Lancet review of billions of administered doses confirms mRNA vaccines are 87% effective against documented SARS-CoV-2 (搜索) infection, 93% against hospitalization, and 94% against death within 14–42 days post-vaccination.
Serious adverse events including myocarditis (搜索) (12.6–35.6 cases per million doses) and anaphylaxis (4.7 per million) remain exceedingly rare, with risks far lower than those from SARS-CoV-2 (搜索) infection itself.
Protection waned over time and against the Omicron lineage (67% against infection, 72% against hospitalization), but booster doses restored much of the lost immunity.
A sweeping review published in The Lancet has provided the most comprehensive assessment to date of mRNA vaccine safety and effectiveness, drawing on data from laboratory research, clinical trials, and real-world surveillance encompassing billions of administered doses globally. The analysis affirms that mRNA vaccines remain highly effective at preventing severe COVID-19 (搜索) outcomes while serious adverse events continue to be exceedingly rare.
The review found that within 14 to 42 days of vaccination, mRNA vaccines were 87% effective against any documented SARS-CoV-2 (搜索) infection, 93% effective at preventing hospitalization, and 94% effective at preventing death. These figures represent a synthesis of data across multiple clinical trials and real-world observational studies conducted worldwide since the vaccines' initial emergency use authorization.
"Across billions of administered doses, serious adverse events have been rare, well characterised, and consistently outweighed by the substantial protection conferred against severe disease, hospitalisation, and death," the researchers stated.
Safety Profile Across Billions of Doses
The review meticulously catalogued adverse event rates from real-world surveillance systems. Myocarditis (搜索) and pericarditis (搜索)—heart-related inflammatory conditions—were observed at rates of approximately 12.6 cases per million doses for Pfizer-BioNTech (搜索)'s BNT162b2 vaccine and about 35.6 cases per million for Moderna's mRNA-1273, with higher incidence among second-dose recipients. Critically, the increased risk of myocarditis and pericarditis from mRNA COVID-19 (搜索) vaccines, particularly in males aged 12–19, was significantly lower than the risk of developing the same conditions from a SARS-CoV-2 (搜索) infection itself.
Other serious adverse events were similarly rare: anaphylaxis occurred at a rate of 4.7 cases per million doses for the Pfizer vaccine, while Guillain-Barré Syndrome was documented at 38 cases per million doses for the AstraZeneca vaccine. Most other side effects—including sore arms, fatigue, and fever—were mild to moderate and resolved within a few days.
"Effectiveness has been shown across age groups, in pregnancy, and in populations that are immunocompromised, establishing mRNA vaccines as a clinically validated and adaptable platform," the authors noted.
Waning Immunity and the Role of Boosters
The analysis confirmed that vaccine effectiveness declined over time and was reduced against the Omicron lineage, dropping to 67% against infection and 72% against hospitalization. However, booster doses restored much of the lost immunity, underscoring the importance of ongoing booster programs as new variants continue to emerge.
Ongoing surveillance and real-world monitoring continue to support the vaccines' tolerability and effectiveness, with the authors emphasizing the need for sustained post-licensure safety monitoring and long-term follow-up to study real-world performance of existing licensed mRNA vaccines.
"Our comprehensive review provides compelling evidence confirming that approved mRNA vaccines are safe and highly effective. Throughout the COVID-19 (搜索) pandemic, mRNA vaccines demonstrated what rapid, science-driven collaboration can achieve by delivering safe, effective protection at an unprecedented scale," said lead study author Dr. Anna Blakney of the University of British Columbia. "The key lessons from mRNA vaccine use during the COVID-19 pandemic are not only about manufacturing speed, but about the importance of sharing safety data, conducting ongoing rigorous real-world surveillance, and providing clear information about how new types of vaccines work and why they protect communities."
Beyond COVID-19 (搜索): A Platform for the Future
The review highlights the versatility of the mRNA platform beyond infectious diseases. Efforts are already underway to develop mRNA-based vaccines against influenza, RSV, and other infectious diseases. The authors also point to the potential for personalized cancer vaccines tailored to individual patients and tumor profiles, as well as RNA-based therapeutics for autoimmune conditions.
"mRNA vaccines have already transformed how we respond to emerging diseases, and with ongoing innovation and rigorous safety monitoring, they can drive progress in preventive medicine and cancer treatment for years to come," said co-author Dr. Manish Sadarangani of the University of British Columbia and BC Children's Hospital Research Institute.
The mRNA platform's inherent advantages include a common manufacturing backbone that can be rapidly adjusted to new targets, a tightly controlled production process that maintains RNA purity and efficacy, and scalability that proved critical during the pandemic response.
Equitable Access Remains a Challenge
Despite the scientific achievements, the researchers cautioned that technological advances alone will not guarantee equitable global access. Improvements in formulation and distribution—including higher-temperature storage options and freeze-drying techniques—are helping vaccines reach remote locations more quickly while reducing waste. However, structural barriers persist.
"Expanding manufacturing capacity and ensuring equitable access in low- and middle-income countries is essential if mRNA vaccines are to fulfil their promise as a global public good," said co-author Dr. Robin Shattock of Imperial College London. "By investing in technology transfer, local production, and robust regulatory systems, we can shorten supply chains, reduce costs, and ensure that people everywhere benefit from safe, effective vaccines beyond pandemics."
The authors acknowledged several study limitations, including that findings were drawn from many different countries and programs, meaning results may vary by population, vaccine product, and how safety data are collected. They also stressed the importance of documenting all instances of side effects, no matter how rare, as some signals might be missed or misinterpreted in real-world observational studies. Finally, the ongoing evolution of viruses means that effectiveness might change with new variants, necessitating continued vigilance.